Asian neTwork for Translational Research and Cardiovascular Trials ("ATTRaCT")
1 other identifier
observational
815
1 country
1
Brief Summary
To build on Singapore's competitive advantages in advanced cardiac imaging, genetic and molecular studies to develop an integrated "one -stop" platform spanning from human to large and small animal models, dedicated to deepening the understanding of CV disease progression, discovery of new targets and repurposing of drugs.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2015
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2015
CompletedFirst Submitted
Initial submission to the registry
May 30, 2016
CompletedFirst Posted
Study publicly available on registry
June 6, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
March 31, 2021
CompletedApril 5, 2024
August 1, 2023
5.7 years
May 30, 2016
April 4, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
First occurrence of cardiovascular event.
3 Year
Study Arms (4)
Diagnosed Heart Failure [Prior]
Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
Control [Prior]
Control will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
Control [New]
Control will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
Diagnosed Heart Failure [New]
Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection, Cognitive Test and Clinical Assessment.
Interventions
CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
Blood will be drawn for circulating biomarkers, which are measurable indicators of the severity or presence of the heart failure condition.
Check health status, blood pressure, heart rate, height and weight measured. In addition, subject will undergo a heart examination.
To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help the investigators understand the type and severity of heart failure.
To relate the presence and severity of cognitive impairment (CI) with simultaneously acquired advanced cardiovascular imaging characteristics and circulating biomarkers of cardiovascular function, inflammation and coagulation.
Eligibility Criteria
800 diagnosed heart failure patient will be recruited from primary care clinic, outpatient clinics and hospital ward from Singapore (NUHCS, NHCS, TTSH, CGH, KTPH, SGH). 800 healthy volunteer control.
You may qualify if:
- Age 21-99
- Present to hospital with diagnosis of HF, or
- Attending a hospital clinic for management of HF within 6/12 of an episode of decompensated heart failure\* which either:
- Resulted in a hospital admission (primary diagnosis) or
- Was treated in out-patient clinic \* Appropriate symptoms and signs of HF, confirmed by PI when necessary
You may not qualify if:
- HF primary due to severe valve disease
- The primary diagnosis is an Acute coronary syndrome (ACS) which has resulted in a transient episode of Acute pulmonary oedema (APO) (Note: Patients with a troponin rise noted during the index admission, but in whom the main presentation is considered clinically to the HF will be included)
- End stage renal failure (eGFR \< 15ml/min/m2) or is receiving or planned to receive renal replacement therapy.
- Other specific subgroups of HF (Including constrictive pericarditis, complex adult congenital heart disease, hypertrophic cardiomyopathy, eosinophilic myocarditis, cardiac amyloid and acute chemotherapy-induces cardiomyopathy)
- Isolated right heart failure\*\* (combined right and left heart failure will be included). (Secondary to severe lung disease or pulmonary hypertension)
- Life threatening co-morbidity with a life expectancy of \< 1 year
- Inability to provide informed consent
- The patient is unable to comply with study protocol requirements
- The patient is participating in another clinical research trial(only if that study precludes involvement in an observational study)
- The patient has declined to participate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- National Heart Centre Singaporelead
- Singapore General Hospitalcollaborator
- National University Hospital, Singaporecollaborator
- Tan Tock Seng Hospitalcollaborator
- Khoo Teck Puat Hospitalcollaborator
- Changi General Hospitalcollaborator
Study Sites (1)
National Heart Centre Singapore
Singapore, 169609, Singapore
Biospecimen
Specific biomarker profiles
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Carolyn Lam, MBBS
National Heart Centre Singapore
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 30, 2016
First Posted
June 6, 2016
Study Start
August 1, 2015
Primary Completion
March 31, 2021
Study Completion
March 31, 2021
Last Updated
April 5, 2024
Record last verified: 2023-08
Data Sharing
- IPD Sharing
- Will not share